🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Intracoronary Hypothermia as a Prevention of Reperfusion Injury in Myocardial Infarction.

RecruitingNAAges 18 Years - 90 YearsAllTomsk National Research Medical Center of the Rus…
NCT06567249 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Acute myocardial infarction with ST segment elevation is often accompanied by a totally occluded coronary artery. Which has deleterious effects on heart muscle. Primary percutaneous coronary intervention is the most effective mode of treatment for ST-elevation myocardial infarction (STEMI) patients. Despite the restoration of the blood flow, 30-60% of patients develop microvascular obstruction, which lowers the effects of the coronary blood flow restoration. The most advanced coronary microvascular obstruction presents as a no-reflow phenomenon, which is an abrupt deceleration or absence of coronary flow following stent implantation. Several pharmacological treatments have been proposed, as well as deferred stenting, but none of them really helped. Thus, new ways of alleviating coronary obstruction are warranted. One of the new ways of mitigating the reperfusion injury is intracoronary h

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Acute ST-elevation myocardial infarction * Time from onset of symptoms less than 12 hours * Given informed consent Exclusion Criteria: * Contraindication to MRI * Cardiogenic shock * Conduction disturbance: Atrioventricular block: 2nd and 3rd degree. SA block. * Sick sinus syndrome requiring implantable pacemaker * Pulmonary edema * Active inflammatory condition * Active chemo/radiation therapy
💊

What it tests

  • Intracoronary hypothermia
  • Standard percutaneous coronary intervention
📍

Where

1 site
Cardiology Research Institute, Tomsk National Research Medical Center
Tomsk, Russia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy